Delirium Market Research Report Information By Drug (First-generation Antipsychotics, Second-generation Antipsychotics and Benzodiazepines), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies and Online Pharmacies), By Type (Hyperactive, Hypoactive and Mixed), By Diagnosis (Laboratory Tests, Physical Examination, Imaging Test, Blood Test and Urine Test), By End-User (Hospitals, Research Centers and Specialty Centers), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Delirium Market Overview

Delirium Market Size was valued at USD 0.25 Billion in 2022. The delirium market industry is projected to grow from USD 0.264 Billion in 2023 to USD 0.4117 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.70% during the forecast period (2023 - 2032). The market for delirium is primarily being driven by the increased prevalence of neurological illnesses, which are brought on by a number of related triggering factors, such as genetic flaws, congenital abnormalities, nerve injuries, etc. Additionally, the extensive use of drugs like benzodiazepines and antipsychotics for treating delirium's symptoms including agitation, hallucinations, and delusions is another important market driver.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Delirium Market Trends

• Rising older population is driving the market growth

The ageing of the world's population has increased the prevalence of age-related disorders that can cause delirium, including dementia, infections, and other ailments. Age-related disorders like dementia, Alzheimer's disease, Parkinson's disease, and other chronic illnesses are more common as the population ages. These illnesses are known delirium risk factors, and the elderly population's higher prevalence of them adds to the rise in delirium instances. Furthermore, due to aging-related changes in the brain, numerous co-morbidities, polypharmacy (the use of various medications), and the existence of other risk factors such sensory impairments, frailty, and cognitive loss, older persons are more prone to delirium. Effective management techniques and interventions are required due to the ageing population's increased susceptibility to delirium.

The delirium market CAGR is significantly influenced by greater understanding and acceptance of delirium. With more knowledge, medical personnel are better able to identify and diagnose delirium. They have received training to distinguish between delirium and other diseases like dementia or depression and to recognize the distinctive symptoms of delirium. More accurate prevalence estimates and effective delirium case management result from improved detection and diagnosis. Delirium has also been introduced into the curricula of medical education programmes, continuing medical education (CME) courses, and healthcare professional training. By doing this, it is made sure that healthcare workers from a range of disciplines, such as doctors, nurses, and allied healthcare professionals, have a thorough grasp of delirium.

Research institutes and industry players are doing research and development (R&D) activities to look into the efficacy and safety of drugs for the treatment of agitation and delirium in critically ill ICU patients. New first-generation antipsychotic drugs are being introduced by a number of businesses in the market to treat delirium, which is anticipated to fuel market revenue growth for delirium management ly. The market is experiencing revenue growth due to an increase in pharmaceutical R&D activity for the symptomatic and targeted treatment of delirium. Doctors and people can be informed about the sickness because the general public is still unaware of how common certain diseases are. This presents an opportunity for researchers and inventors to develop a potent delirium treatment in order to sustain market growth. Thus, driving the delirium market revenue.

Delirium Market Segment Insights

Delirium Drug Insights

The  delirium market segmentation, based on drug includes First-generation Antipsychotics, Second-generation Antipsychotics and Benzodiazepines. The second-generation antipsychotics segment dominated the market. These medications' reduced affinity for dopamine receptors will lessen their adverse effects. This is the reason that the market need for  delirium management is increasing.

Delirium Distribution Channel Insights

The  delirium market segmentation, based on distribution channel, includes Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. The hospital pharmacies category generated the most income. The hospital pharmacy provides patients with care that maximizes the use of medications while fostering wellness, health, and illness prevention. Additionally, they assure the highest level of safety in the dispensing of medicines and possess professional skills and ethics. As a result, the patient's condition will be steady throughout the full pharmacological therapy.

Delirium Type Insights

The  delirium market segmentation, based on type, includes Hyperactive, Hypoactive and Mixed. The hyperactive category generated the most income. Patients display hyperactivity, agitation, and restlessness. They could be physically or verbally aggressive, speak quickly, and have trouble sitting still or remaining still.

Figure 1  Delirium Market, by Type, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Delirium Diagnosis Insights

The  delirium market segmentation, based on diagnosis, includes Laboratory Tests, Physical Examination, Imaging test, Blood test and Urine test. The laboratory tests category generated the most income. For the purpose of figuring out possible underlying causes of delirium, laboratory testing may be carried out. These examinations could involve blood tests to check for infection markers, liver and kidney function, blood glucose levels, and electrolyte levels.

Delirium End-User Insights

The  delirium market segmentation, based on end-user, includes hospitals, Research Centers and Specialty Centers. The hospitals category generated the most income. Hospitals have a significant role in the diagnosis, administration, and management of delirium. In these environments, medical experts such as doctors, nurses, and specialists evaluate patients, administer medicinal interventions, and track the development of delirium cases.

Delirium Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American delirium market area will dominate this market due to the localization of new therapy alternatives. Growing adoption of various breakthroughs in mental health treatment alternatives is being fueled by rising rates of suicidal ideation and mental health illnesses in the region. Better delirium treatment alternatives are also in demand due to the public's growing awareness of mental health issues in the wake of the COVID-19 pandemic.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  DELIRIUM MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe delirium market accounts for the second-largest market share. The availability of treatment options and rising healthcare costs would both contribute to the market's ability to grow in terms of revenue. Over the course of the forecast year, these variables are anticipated to propel market revenue growth for delirium in the area. Further, the German delirium market held the largest market share, and the UK delirium market was the fastest growing market in the European region

The Asia-Pacific Delirium Market is expected to grow at the fastest CAGR from 2023 to 2032 due to an increase in the number of elderly people in several nations, notably China and India. Additional factors that are anticipated to contribute to the market's revenue growth over the projected period include the presence of generic manufacturers and the expansion of healthcare facilities in the area. Moreover, China’s delirium market held the largest market share, and the Indian delirium market was the fastest growing market in the Asia-Pacific region.

Delirium Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the delirium market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, delirium industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  delirium industry to benefit clients and increase the market sector. In recent years, the delirium industry has offered some of the most significant advantages to market. Major players in the delirium market attempting to increase market demand by investing in research and development operations include Dr. Franz Kohler Chemie GmbH, Fraser Health, Gaia BioPharma Ltd., Novartis AG, Pfizer, Inc., Regenstrief Institute, Inc., and Air Liquide Sante International, among others.

Biopharmaceuticals are discovered, developed, produced, and sold by Pfizer Inc. The business sells goods to cure a range of ailments, including cancer, inflammation, rare diseases, metabolic, cardiovascular, and metabolic and pain disorders, as well as women's health issues. Additionally, it offers contract manufacturing services, sterile injectable drugs, biosimilars, active pharmaceutical ingredients (APIs), and medicines. Pfizer offers its goods through distributors, merchants, pharmacies, hospitals, private physician offices, clinics, and public institutions.

Based in Basel, Switzerland, Novartis AG is a multinational pharmaceutical company. One of the biggest pharmaceutical firms in the world and the fourth largest by sales in 2022, Novartis is consistently listed in the top five worldwide. As a preeminent  pharmaceutical firm, we develop ground-breaking therapies in areas of urgent medical need using cutting-edge research and digital technology. It constantly ranks among the top corporations in the world that invest in research and development in the search for novel medications. ly, approximately 800 million people use pharmaceuticals made by Novartis, and we are constantly looking for new, creative methods to increase access to our most recent treatments. Worldwide, Novartis employs about 108,000 employees from more than 140 different countries.

Key Companies in the delirium market include

• Franz Kohler Chemie GmbH


• Fraser Health


• Gaia BioPharma Ltd.


• Novartis AG


• Pfizer, Inc.


• Regenstrief Institute, Inc.


• Air Liquide Sante International

Delirium Industry Developments

June 2021 The ALKERMES plc product LYBALVITM (olanzapine and samidorphan) has received FDA approval for the acute treatment of mixed episodes, either as a monotherapy or as an adjunct to lithium or valproate. This approval covers adults with schizophrenia and adults with bipolar I disorder. The antipsychotic olanzapine and the novel chemical samidorphan are combined to form the oral, once-daily atypical antipsychotic medication LYBALVI.

December 2020 Aurobindo Pharma has been awarded permission by the U.S. Food and Drug Administration (FDA) to manufacture and distribute dexmedetomidine hydrochloride in 0.9% sodium chloride injection, 200 g/50 mL, and 400 g/100 mL Single Dose flexible containers (Bags). It is a somewhat selective alpha2-adrenergic agonist that is advised for use in the management of intubated and mechanically ventilated patients in critical care units as well as non-intubated patients before and/or during surgery.

September 2020 Dexmedetomidine Hydrochloride was first made available by Dr. Reddy's Laboratories in the 0.9% Sodium Chloride Injection form for the sedation of newly intubated and mechanically ventilated patients in an intensive care setting for the treatment of hyperactive delirium (agitation in delirium). The FDA has approved a therapeutically equivalent generic version of Precedex (dexmedetomidine hydrochloride) in 0.9% sodium chloride injection form (USFDA).

June 2020 According to Aurania, Otsuka, a licencing partner, will receive marketing authorization and have its application placed under delirium management.

Delirium Market Segmentation

Delirium Drug Outlook (USD Billion, 2018-2032)

• First-generation Antipsychotics


• Second-generation Antipsychotics


• Benzodiazepines

Delirium Distribution Channel Outlook (USD Billion, 2018-2032)

• Retail Pharmacies


• Hospital Pharmacies


• Online Pharmacies

Delirium Type Outlook (USD Billion, 2018-2032)

• Hyperactive


• Hypoactive


• Mixed

Delirium Diagnosis Outlook (USD Billion, 2018-2032)

• Laboratory Tests


• Physical Examination


• Imaging test


• Blood test


• Urine test

Delirium End-User Outlook (USD Billion, 2018-2032)

• Hospitals


• Research Centers


• Specialty Centers

Delirium Regional Outlook (USD Billion, 2018-2032)

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America
  
  
  
  

Report Scope:

Delirium Report Scope

Report Attribute/Metric	Details
Market Size 2022	USD 0.25 Billion
Market Size 2023	USD 0.264 Billion
Market Size 2032	USD 0.4117 Billion
Compound Annual Growth Rate (CAGR)	5.70% (2023-2032)
Base Year	2022
Market Forecast Period	2023-2032
Historical Data	2018- 2022
Market Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered	Drug, Distribution Channel, Type, Diagnosis, End-User, and Region
Geographies Covered	North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered	The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled	Dr. Franz Kohler Chemie GmbH, Fraser Health, Gaia BioPharma Ltd., Novartis AG, Pfizer, Inc., Regenstrief Institute, Inc., and Air Liquide Sante International, among others
Key Market Opportunities	Increasing government initiatives  Increasing programs to create awareness
Key Market Dynamics	Increasing prevalence of neurological disorders  Increasing older population

Frequently Asked Questions (FAQ) :